Fluoroethylnormemantine, a derivative of Memantine, acts as an N-methyl-D-aspartate (NMDA) receptor antagonist. It can function as a positron emission tomography (PET) tracer, known as [18F]-fluoroethylnormemantine. This compound displays anti-amnesic, neuroprotective, antidepressant-like, and fear-attenuating properties.

Fluoroethylnormemantine (0.1-10 mg/kg; a single i.p.) shows anti-amnesic effects on Aβ 25-35 -induced learning impairments in mice[1]. Fluoroethylnormemantine (0.1-10 mg/kg; i.p. once daily for 7 days) attenuates Aβ 25-35 -induced behavioral deficits, neuroinflammation, oxidative stress, apoptosis, and cell loss in mice[1]. Fluoroethylnormemantine (1-20 mg/kg; a single injection) decreases behavioral despair in the forced swim test (FST) and reduces fear behavior in the cued fear conditioning (FC) and extinction training in rats[2]. Animal Model: Male Swiss CD-1 mice (7-9 weeks) were injected with Aβ 25-35[1]Dosage: 0.1, 0.3, 1, 3, 10 mg/kg Administration: I.p. 30 minutes before the behavioral tests Result: Attenuated Aβ 25-35 -induced spontaneous alternation deficit, passive avoidance deficit, and novel object exploration deficit.